These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8104681)

  • 21. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma.
    Tauchi K; Hori S; Itoh H; Osamura RY; Tokuda Y; Tajima T
    Virchows Arch A Pathol Anat Histopathol; 1989; 416(1):65-73. PubMed ID: 2573192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of pS2 protein in endometrial carcinomas: correlation with clinicopathologic features and sex steroid receptor status.
    Koshiyama M; Yoshida M; Konishi M; Takemura M; Yura Y; Matsushita K; Hayashi M; Tauchi K
    Int J Cancer; 1997 Jun; 74(3):237-44. PubMed ID: 9221798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.
    Bonneterre J; Hutt E; Bosq J; Graham JD; Powell MA; Leblanc E; Fujiwara K; Herzog TJ; Coleman RL; Clarke CL; Gilles EM; Zukiwski AA; Monk BJ
    Gynecol Oncol; 2015 Sep; 138(3):663-7. PubMed ID: 26142884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptors in human breast and endometrial carcinomas.
    Llorens MA; Bermejo MJ; Salcedo MC; Charro AL; Puente M
    J Steroid Biochem; 1989; 34(1-6):505-9. PubMed ID: 2626045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
    Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
    Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
    Reinartz JJ; George E; Lindgren BR; Niehans GA
    Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Panel of Villin, Pro-Ex-C, Estrogen Receptor and Progesterone Receptor Expressions Could Help in Differentiation Between Endocervical and Endometrioid Adenocarcinoma.
    Elfeky M; Harb O; Gertallah L
    Turk Patoloji Derg; 2017; 1(1):29-40. PubMed ID: 28832070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
    Yu CG; Jiang XY; Li B; Gan L; Huang JF
    Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Microsatellite instability in endometrial neoplasms correlation with clinicopathologic parameters and estrogen receptor or progesterone receptor status].
    Song Y; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):273-6. PubMed ID: 11775905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
    Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
    Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Correlation with clinicopathology, sex steroid receptor status, and p53 protein expression.
    Nanbu K; Konishi I; Komatsu T; Mandai M; Yamamoto S; Kuroda H; Koshiyama M; Mori T
    Cancer; 1996 Jan; 77(2):330-8. PubMed ID: 8625242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content.
    Prat J; Oliva E; Lerma E; Vaquero M; Matías-Guiu X
    Cancer; 1994 Sep; 74(6):1778-83. PubMed ID: 7915964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical studies on oncogene products (EGF-R, c-erbB-2) and growth factors (EGF, TGF-alpha) in human breast cancer: their relationship to oestrogen receptor status, histological grade, mitotic index and nodal status.
    Umekita Y; Enokizono N; Sagara Y; Kuriwaki K; Takasaki T; Yoshida A; Yoshida H
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(4):345-51. PubMed ID: 1348890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selected immunohistochemical prognostic factors in endometrial cancer.
    Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
    Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
    Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
    Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
    Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
    J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.